Non-compaction cardiomyopathy. Part I: clinical and genetic heterogeneity and predictors of unfavorable prognosis

Non-compaction cardiomyopathy (NCM) is a rare heart disease characterized by a two-layered ventricular wall, comprising a thinner compact epicardial layer and an inner non-compacted layer. However, only structural and morphological data without a thorough clinical assessment does not determine the NCM (regardless of the diagnostic criterion used).
Aim. To study the NCM-related genes, phenotypic and genetic correlations, predictors of life-threatening ventricular tachyarrhythmias (VTA) and adverse clinical outcomes.
Material and methods. Of 93 individuals with identified morphological criteria of NCM (median follow-up, 5 years), the study included 60 unrelated patients (38,5±13,8 years of age; men, 33 (55%); left ventricular ejection fraction (LVEF), 42,1±12,9%) with clinical verification of NCM (>1 obligate phenotypic trait). Adverse cardiovascular events were taken as the composite end point: life-threatening VTA, death, heart transplantation.
Results. Pathogenic (or probably pathogenic) mutations were detected in 33 (55%) patients with NCM. The most common variants (57,9%) were identified in the sarcomere protein genes (TTN, MYBPC3, MYH7); digenic mutations were found in 21,6% of patients. Digenic mutations were associated with low LVEF and the highest risk of systolic dysfunction (OR, 38; 95% CI, 4,74-305; p=0,0001). Multivariate regression provided a predictive model (R=0,90; R2=0,81; F (5,41) =34,8; p<0,0001) and independent predictors of adverse clinical outcomes of NCM (genetic cause of the disease (pathogenic mutation), LV systolic dysfunction, myocardial fibrosis in 2 or more ventricular segments, and QRS prolongation. Regression and ROC-analysis identified electrical predictors of life-threatening VTA (fragmented QRS, QT prolongation, spatial QRS-T angle increase) and morphofunctional markers (myocardial fibrosis, systolic dysfunction).
Conclusion. The study revealed a significant clinical and genetic heterogeneity of NCM with predominant mutations in the sarcomeric protein genes and determined the criteria for identification and prognosis of NCM.

1. Arbustini E, Weidemann F, Hall JL. Left ventricular noncompaction. J Am Coll Cardiol. 2014;64:1840-50. doi:10.1016/j.jacc.2014.08.030.

2. Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet. 2015;386:813-25. doi:10.1016/S0140-6736(14)61282-4.

3. Nucifora G, Aquaro GD, Masci PG, et al. Magnetic resonance assessment of prevalence and correlates of right ventricular abnormalities in isolated left ventricular noncompaction. Am J Cardiol. 2014;113:142-6. doi:10.1016/j.amjcard.2013.08.049.

4. Oechslin E, Jenni R. Left ventricular noncompaction. J Am Coll Cardiol. 2018;71:723-6. doi:10.1016/j.jacc.2017.12.031.

5. Kovacevic-Preradovic T, Jenni R, Oechslin EN, et al. Isolated left ventricular noncompaction as a cause for heart failure and heart transplantation: a single center experience. Cardiology. 2009;112:158-64. doi:10.1159/000147899.

6. Gati S, Papadakis M, Papamichael ND, et al. Reversible de novo left ventricular trabeculations in pregnant women: implications for the diagnosis of left ventricular noncompaction in low-risk populations. Circulation. 2014;130:475-83. doi:10.1161/circulationaha.114.008554.

7. Gati S, Chandra N, Bennett RL, et al. Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non-compaction in athletes? Heart. 2013;99:401-8. doi:10.1136/heartjnl-2012-303418.

8. Minamisawa M, Koyama J, Kozuka A, et al. Regression of left ventricular hypertrabecula-tion is associated with improvement in systolic function and favorable prognosis in adult patients with non-ischemic cardiomyopathy. J Cardiol. 2016;68:431-8. doi:10.1016/j.jjcc.2015.11.008.

9. Caselli S, Attenhofer Jost CH, Jenni R, et al. Left ventricular noncompaction diagnosis and management relevant to pre-participation screening of athletes. Am J Cardiol. 2015;116:801-8. doi:10.1016/j.amjcard.2015.05.055.

10. Stahli B, Gebhard C, Biaggi P, et al. Left ventricular non-compaction: prevalence in congenital heart disease. Int J Cardiol. 2013;167:2477-81. doi:10.1016/j.ijcard.2012.05.095.

11. van Waning JI, Caliskan K, Hoedemaekers YM, et al. Genetics, clinical features, and longterm outcome of noncompaction cardiomyopathy. J Am Coll Cardiol. 2018;71:711-22. doi:10.1016/j.jacc.2017.12.019.

12. Jenni R, Oechslin E, Schneider J, et al. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart. 2001;86:666-71. doi:10.1136/heart.86.6.666.

13. Stollberger C, Finsterer J, Blazek G. Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. Am J Cardiol. 2002;90:899-902. doi:10.1016/S0002-9149(02)02723-6.

14. Petersen SE, Selvanayagam JB, Wiesmann F, et al. Left ventricular non-compaction. J Am Coll Cardiol. 2005;46:101-5. doi:10.1016/j.jacc.2005.03.045.

15. Jacquier A, Thuny F, Jop B, et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J. 2010;31:1098-104. doi:10.1093/eurheartj/ehp595.

16. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24. doi:10.1038/gim.2015.30.

17. Vaikhanskaya TG, Sivitskaya LN, Kurushko TV, et al. Non-Compact Cardiomyopathy: Clinical-Genetic Analysis (the First Experience in Belarus). Cardiology in Belarus. 2019;11(5):678-97.

18. Andreini D, Pontone G, Bogaert J, et al. Long-term prognostic value of cardiac magnetic resonance in left ventricle noncompaction: a prospective multicenter study. J Am Coll Cardiol. 2016; 68:2166-81. doi:10.1016/j.jacc.2016.08.053.

19. Zhou H, Lin X, Fang L, et al. Prolonged QTc indicates the clinical severity and poor prognosis in patients with isolated left ventricular noncompaction. Int J Cardiovasc Imaging. 2017;33:2013-20. doi:10.1007/s10554-017-1209-9

20. Cetin MS, Ozcan Cetin EH, Canpolat U, et al. Usefulness of fragmented QRS complex to predict arrhythmic events and cardiovascular mortality in patients with noncompaction cardiomyopathy. Am J Cardiol. 2016;117:1516-23. doi:10.1016/j.amjcard.2016.02.022.

21. Zhou H, Lin X, Fang L, et al. Characterization of compacted myocardial abnormalities by cardiac magnetic resonance with native T1 mapping in left ventricular non-compaction patients — a comparison with late gadolinium enhancement. Circ J. 2016;80:1210-16. doi:10.1253/circj.CJ-15-1269.

22. Araujo-Filho JAB, Assuncao ANJr, Tavares de Melo MD, et al. Myocardial T1 mapping and extracellular volume quantification in patients with left ventricular noncompaction cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2018;19:888-95. doi:10.1093/ehjci/jey022.

23. Miller EM, Hinton RB, Czosek R, et al. Genetic testing in pediatric left ventricular noncompaction. Circ Cardiovasc Genet. 2017;10(6):e001735. doi:10.1161/circgenetics.117.001735.

24. Ichida F. Left ventricular noncompaction — Risk stratification and genetic consideration. Journal of Cardiology. 2020;75(1):1-9. doi:10.1016/j.jjcc.2019.09.011.

25. Negri F, De Luca A, Fabris E, et al. Left ventricular noncompaction, morphological, and clinical features for an integrated diagnosis. Heart Fail Rev. 2019;24(3):315-323. doi:10.1007/s10741-018-9763-3.